Novel Immunotherapy Targets CancerS Shield, Showing Promise in Preclinical Trials
A groundbreaking immunotherapy developed by researchers at the Icahn School of Medicine at Mount Sinai is offering a new strategy in the fight against metastatic cancer. Unlike conventional approaches that directly target cancer cells, this innovative treatment focuses on dismantling the protective environment surrounding tumors, potentially unlocking new avenues for patients with advanced and treatment-resistant cancers.The findings, published in Cancer Cell, demonstrate important efficacy in preclinical models of aggressive ovarian and lung cancers.
The Trojan Horse Approach to Cancer Treatment
For decades, immunotherapy has sought to harness the power of the immune system to fight cancer. However, solid tumors often erect a formidable defense, suppressing immune activity and shielding cancer cells from attack. The Mount Sinai team, led by Jaime Mateus-Tique, PhD, and Brian Brown, PhD, has taken a novel approach, drawing inspiration from the ancient tale of the Trojan horse.
instead of attempting to breach the tumor’s defenses directly, the researchers designed a therapy to infiltrate the tumor by targeting tumor-associated macrophages (TAMs). These immune cells, normally responsible for fighting infection and repairing tissue damage, are often co-opted by cancer cells to create a protective barrier. by disabling these “guardians,” the treatment effectively opens the tumor to immune attack.
“What we call a tumor is really cancer cells surrounded by cells that feed and protect them – a walled fortress,” explains Dr. Mateus-Tique. “We realized that instead of trying to break down the walls, we could target the guards, turn them from protectors to friends, and use them as a gateway to bring a wrecking force within the fortress.”
Reprogramming Immune Cells with CAR T-Cell Therapy
The immunotherapy utilizes Chimeric Antigen Receptor (CAR) T-cell therapy, a technique where a patient’s own T cells are engineered to recognise and destroy specific targets. Traditionally, CAR T-cells are designed to target cancer cells directly.However,identifying suitable targets on solid tumors has proven challenging.
The Mount Sinai team overcame this hurdle by redirecting CAR T-cells to recognize and eliminate TAMs. Furthermore, they modified the CAR T-cells to release interleukin-12 (IL-12), a potent immune-stimulating molecule that activates killer T cells, amplifying the immune response within the tumor.
In experiments with mice bearing metastatic lung and ovarian cancer, the engineered CAR T-cells demonstrated remarkable results. Animals treated with the therapy experienced considerably prolonged survival, with many achieving complete tumor remission.
Reshaping the Tumor microenvironment for Broad Applicability
Advanced spatial genomics analyses revealed that the treatment dramatically reshaped the tumor microenvironment. By removing immune-suppressing TAMs, the therapy facilitated the influx of immune cells capable of killing cancer. This shift is particularly significant because it renders the therapy “antigen-autonomous,” meaning it doesn’t rely on identifying specific markers on cancer cells.
“Macrophages are found in every type of tumor,sometimes outnumbering the cancer cells,” says Dr.Brown, Director of the icahn Genomics Institute.”What’s so exciting is that our treatment converts these cells from protecting the cancer to killing it. We’ve turned foe into ally.”
This antigen-independent nature suggests the therapy could be applicable to a wide range of cancers, including those that have proven resistant to conventional immunotherapies. The success observed in both lung and ovarian cancer models further supports its potential broad applicability.
Future Directions and Clinical Trials
While these preclinical results are highly promising, the researchers emphasize that clinical trials are necessary to determine the safety and efficacy of the therapy in humans.The current focus is on refining the approach, particularly optimizing the delivery and release of IL-12 within tumors to maximize therapeutic impact while minimizing potential side effects.
The team envisions this strategy as a foundation for future CAR T-cell therapies that target the support cells surrounding tumors, rather than the cancer cells themselves, offering a potentially transformative approach to cancer treatment.
Keywords:
* Primary Topic: Cancer Immunotherapy
* Primary Keyword: Metastatic cancer Treatment
* Secondary Keywords: CAR T-cell therapy, tumor microenvironment, tumor-associated macrophages, immunotherapy resistance, ovarian cancer, lung cancer, cancer research, precision medicine, interleukin-12, immune-oncology.
Keep reading